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    A B S T R A C T          Objectives    To compare the effects of two monophasic combined oral contraceptives, 
containing either nomegestrol acetate/17  β  -oestradiol (NOMAC/E2) or levonorgestrel/ 
ethinylestradiol (LNG/EE) on endocrine function, androgens, and sex hormone-binding 
globulin (SHBG).     
     Methods    Randomised, open-label, multi-centre trial involving 121 healthy women, aged 
18  –  50 years old. Participants received NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen 
(  n        60) or LNG/EE (150   µ  g/30   µ  g) in a 21/7-day regimen (  n        61) for six cycles. The 
primary outcome was the change from baseline to cycle 6 in markers of adrenal and thyroid 
function, androgens, and SHBG.     
     Results    Total cortisol, corticosteroid-binding globulin (CBG), and thyroxine-binding 
globulin (TBG) increased from baseline in both groups, with signiﬁ  cantly greater increases 
in the LNG/EE group. No relevant changes from baseline or differences between the groups 
were observed for thyroid-stimulating hormone (TSH) and free thyroxine (T  4  ). Androgens 
and androgen precursors decreased from baseline in both groups, with signiﬁ  cantly greater 
decreases in the LNG/EE group (except for free testosterone). A greater increase in SHBG 
was observed with NOMAC/E2 than with LNG/EE.     
     Conclusions    NOMAC/E2 has signiﬁ  cantly less inﬂ  uence on markers of adrenal and thy-
roid function and androgens than LNG/EE. The clinical relevance of these ﬁ  ndings requires 
further study.   
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    I N T R O D U C T I O N   
    Combined oral contraceptives (COCs) are the most 
popular form of reversible contraception in the world  1  . 
As COCs have evolved, the two most important formu-
lation changes consisted of a reduction in the dose of 
the oestrogenic component ethinylestradiol (EE) 
from     50   µ  g to       35   µ  g per pill, and the introduction 
of newer progestogens. Together, these changes have 
helped to reduce cardiovascular events, and have improved 
the safety and tolerability proﬁ  les of COCs  2,3  . 
  The incorporation of oestrogens and progestogens 
that are structurally similar or identical to endogenous 
hormones represent the most recent change in the 
evolution of COCs  4,5  . In particular, 17  β  -oestradiol 
(E2) has been investigated as an alternative to synthetic 
EE. Early attempts to incorporate E2 into COCs were 
unsuccessful due to poor cycle control, especially 
when administered as part of a monophasic or bipha-
sic regimen  6  –  9  . Despite these early setbacks, it is still 
hypothesised that the use of E2 in combination with 
a suitable progestogen would improve the safety of 
COCs and patient tolerability  10  . 
  Nomegestrol acetate (NOMAC) is a progestogen 
structurally similar to progesterone that is devoid of 
oestrogenic, androgenic, glucocorticoid, and mineralo-
corticoid activity but it exerts antioestrogenic effects 
on the endometrium and has a moderate antiandro-
genic activity  11  . The combination of NOMAC with 
E2 (NOMAC/E2) was developed as a monophasic 
COC. Previous studies have shown that NOMAC/E2 
administered in a 24/4-day dosing regimen had sup-
pressive effects on the ovaries, cervical mucus and 
endometrium that were at least as strong as those of a 
comparator COC containing drospirenone and EE  12  . 
  Several studies have shown that COCs can affect adre-
nal and thyroid function as well as androgen levels  13  –  15  . 
The objective of this six-cycle study was to determine 
the effects of NOMAC/E2 on surrogate markers of adre-
nal and thyroid function, androgens, androgen precursors, 
and sex hormone-binding globulin (SHBG) in com-
parison to the COC levonorgestrel (LNG)/EE (150 
  µ  g/30   µ  g). The effects of NOMAC/E2 on haemostasis, 
lipids, and carbohydrate metabolism were also assessed in 
this trial and are reported elsewhere  16  .    
    M E T H O D S   
  This study was a randomised, open-label, comparative, 
parallel-design clinical study. Five centres in Finland 
participated in the trial. Advertisements were used to 
recruit women from the regions surrounding the 
study centres (Kuopio, Tampere, Turku, Espoo, and 
Oulu). Throughout the trial, study volunteers were 
compensated for their time, travel costs, and inconve-
nience associated with study visits. 
  The study was conducted in compliance with the 
ethical principles described in the Declaration of Hel-
sinki and the International Conference on Harmoni-
sation (ICH) guideline for Good Clinical Practice 
(GCP). At each study centre, the Independent Ethics 
Committee reviewed and approved the trial protocol 
(NCT00511355). Prior to treatment, written informed 
consent was obtained from all study participants.   
  Participants 
  Healthy, sexually active women aged 18    –    50 years with 
a body mass index (BMI) between 17 and 29 kg/m  2   
were eligible for the study if they had no contraindica-
tions for the use of contraceptive steroids and had not 
taken any other hormonal treatment (except contracep-
tives) within two months prior to screening. The con-
traindications for contraceptives were in line with the 
World Health Organisation  ’ s medical eligibility criteria 
for contraceptive use  17  . Additionally, women were 
excluded from the study if they had an abnormal cervi-
cal smear or a clinically relevant abnormal laboratory 
ﬁ  nding, were breastfeeding, or if they used liver-enzyme-
inducing drugs, investigational drugs, or pharmacological 
agents that can affect haemostasis (e.g., vitamin K, non-
steroidal anti-inﬂ  ammatory drugs, including aspirin).     
  Treatment and study design 
  The objectives of this trial were to assess and compare 
the effects of NOMAC/E2 and LNG/EE on surro-
gate markers of adrenal and thyroid function, andro-
gens, androgen precursors, and SHBG levels. 
  The trial consisted of one pretreatment cycle (cycle 
0), followed by six 28-day treatment cycles (cycles 1    –    6) 
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blood sampling, processing, storage, and shipment was 
provided to the centres by the central laboratory 
(BARC).   
  Surrogate markers of adrenal and thyroid function 
  Electrochemiluminescence immunoassays (ECLIAs; 
Roche Diagnostics) were used to measure serum lev-
els of total cortisol, thyroid-stimulating hormone 
(TSH), and free thyroxine (T  4  ). Radioimmunoassays 
(RIAs) were used to measure corticosteroid-binding 
globulin (CBG; Biosource) and thyroxine-binding 
globulin (TBG; Brahms).     
  Androgens and androgen precursors 
  Total testosterone was measured by ECLIA (Roche Diag-
nostics). Dehydroepiandrosterone sulphate (DHEAS), 
androstenedione, and dihydrotestosterone (DHT) were 
measured by radioimmunoassay (Immunotech; DPC 
Coat A Count, and DPC, respectively). Levels of free 
testosterone were calculated from total testosterone 
and SHBG as described by Vermeulen   et al  .  18  .    
  SHBG 
  Serum SHBG was measured by ECLIA (Roche Diag-
nostics).       
  Statistical analysis 
  The trial was set up to conﬁ  rm the expected differ-
ences in changes from baseline between the treat-
ment groups in several metabolic indices, especially 
prothrombin fragment 1        2, D-dimer, and antith-
rombin III, as reported elsewhere  16  . In short, based 
on expected effect sizes (i.e., differences between the 
treatment groups divided by the standard deviation) 
of 0.6 or higher observed in previous trials, a sample 
size of 42 evaluable participants per treatment group 
was needed using a two-sided statistical test with 
80% power and a signiﬁ  cance level of 5%. This power 
to detect moderately large effect sizes of 0.6 was also 
considered appropriate for surrogate markers of adre-
nal and thyroid function, androgens, and androgen 
precursors assessed in the trial. Compensating for up 
to 20% premature discontinuations from treatment and 
accounting for a potential power loss due to the non-
parametric analysis, in total 60 women were to be 
randomised per treatment group. 
and a post-treatment visit. All study visits in which 
blood samples needed to be taken took place in the 
morning, when participants were fasting. At the screen-
ing visit, eligibility for participation was determined 
and baseline data were collected. Women were instructed 
to discontinue the use of hormonal contraceptives and 
to use condoms whenever necessary. The ﬁ  rst men-
struation after the screening visit was considered a 
withdrawal bleeding, and the pretreatment cycle started 
during the next (  ‘  spontaneous  ’  ) menstrual period. The 
pretreatment cycle visit occurred during the second 
half of this cycle. During this visit, blood was taken for 
baseline assessment of markers of adrenal and thyroid 
function, androgens, androgen precursors, and SHBG. 
This would ensure a period of at least six weeks between 
last contraceptive use and baseline measurements (i.e., 
four weeks until spontaneous menstruation, plus two 
weeks until baseline assessment). 
  Women who were eligible for enrolement were 
randomised in a 1:1 ratio to receive daily either a 
COC containing 2.5 mg NOMAC and 1.5 mg E2, 
or the comparator COC containing 150   µ  g LNG and 
30   µ  g EE. Randomisation was performed using 
blocks with randomly permuted block sizes and an 
interactive voice response system. Due to the broad-
ened age range compared with previous trials with 
COCs, women were stratiﬁ  ed into two age groups 
(18    –    35 years old and 36    –    50 years old) to ensure that 
approximately 20% of the participants were between 
36    –    50 years of age at screening. For six consecutive 
28-day cycles, women took one oral tablet of study 
medication at approximately the same time each day 
(day 1 to day 28). The NOMAC/E2 regimen con-
sisted of 24 days of active pills followed by four days 
of placebo pills; the LNG/EE regimen consisted of 
21 days of active pills followed by seven days of pla-
cebo pills. Between days 15 and 21 of treatment 
cycles 3 and 6, participants returned to the clinic in 
a fasted state and blood was collected. A ﬁ  nal visit 
was scheduled between 8 and 14 days after the last 
tablet was taken in cycle 6 or after early discontinu-
ation of treatment for the gathering of general fol-
low-up data.     
  Laboratory measurements 
  All laboratory examinations were performed by the 
Bio Analytical Research Corporation (BARC) in Gent, 
Belgium. A manual with complete instructions on Effect of NOMAC/E2 on endocrine function/androgens  Å  gren et al.
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  The analyses of the cycle 6 assessments were con-
sidered the primary outcome, whereas the analyses of 
the cycle 3 assessments were regarded as secondary 
outcomes. Analyses were performed for all partici-
pants who had taken at least one tablet of either study 
medication. Summary statistics are presented as mean 
values with standard deviations (SDs) and median 
values with interquartile ranges (IQRs). Data are pre-
sented for baseline (deﬁ  ned as the last measurement 
before administration of the ﬁ  rst study medication) 
and treatment cycles 3 and 6; changes from baseline 
to cycle 6 were calculated per index assessed. All tests 
of statistical signiﬁ  cance were performed at the 5% 
error level. The Cochran-Mantel-Haenszel test, 95% 
conﬁ  dence intervals (CIs; based on the Hodges-Le-
hmann approach  19  ), frequency tables, and descriptive 
statistics were used for data analyses. No correction 
for multiplicity was applied.       
    R E S U L T S   
  A total of 121 women were randomised to receive 
either NOMAC/E2 or LNG/EE (Figure 1). All women 
in the NOMAC/E2 group (  n       60) received treatment, 
whereas three of the women in the LNG/EE group 
(  n        61) did not because of a pretreatment adverse 
event (AE) (  ‘  acne  ’  ), withdrawn consent, or other per-
sonal reason (found a new job). Seven women (11.7%) 
in the NOMAC/E2 group and six women (10.3%) in 
the LNG/EE group discontinued treatment before the 
end of the trial. Of these 13 discontinuers, eight women 
(four in each group) discontinued treatment due to an 
AE, one due to pregnancy wish, one moved to another 
city, and three women were lost to follow-up. Overall 
tablet intake compliance was high in both treatment 
groups: 93.1% and 87.7% of women in the NOMAC/
E2 and LNG/EE groups, respectively, took the daily 
tablet on at least 95% of treatment days. 
  The demographic and clinical characteristics were 
similar between the two treatment groups at baseline 
(Table 1), with the exception of smoking prevalence, 
which was higher among women in the NOMAC/
E2 group. The majority of smokers were light smok-
ers (15.0% and 8.6% of all NOMAC/E2 and LNG/
EE users, respectively), consuming on average less 
than 10 cigarettes per day. Baseline values for all 
measured indices were balanced between the two 
treatment groups (Tables 2    –    4). The mean age was 
28.7 years. All but one of the participants (99.2%) 
were White. The effects on surrogate markers of 
adrenal and thyroid function, androgens, androgen 
precursors, and SHBG were similar for the two age 
groups (18    –    35 years old and 36    –    50 years old). The 
     
Figure 1   Flow chart of participants. NOMAC/E2, nomegestrol acetate/17  β  -oestradiol; LNG/EE, levonorgestrel/
ethinylestradiol.   Effect of NOMAC/E2 on endocrine function/androgens    Å  gren et al.
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greater in the LNG/EE group than in the NOMAC/
E2 group (Table 3). The differences between the 
treatment groups in change from baseline to cycle 6 
were statistically signiﬁ   cant for all androgens and 
androgen precursors (Table 5;   p        0.05) except for 
free testosterone. Both treatments were associated 
with increases in median SHBG concentrations 
(Table 4), with a signiﬁ  cantly greater increase in the 
NOMAC/E2 group (44%) compared with the LNG/
EE group (22%) at cycle 6 (  p       0.019; Table  5). 
  For all androgens, androgen precursors, and SHBG, 
changes from baseline to cycle 3 were in general sim-
ilar to changes from baseline to cycle 6.     
  Contraceptive efﬁ  cacy and tolerability 
  No pregnancies occurred during the trial in either 
treatment group. NOMAC/E2 had a similar AE 
proﬁ  le as LNG/EE, and both COCs were generally 
results are therefore presented only for the age groups 
combined.   
  Analyses related to surrogate markers of 
adrenal and thyroid function 
  Total cortisol, CBG, and TBG concentrations increased 
from baseline to cycle 6 in both treatment groups, 
with a signiﬁ   cantly more pronounced rise in the 
LNG/EE group (Tables 2 and 5;   p       0.001). For TSH 
and free T4, changes from baseline to cycle 6 were 
small, with no statistically signiﬁ  cant  differences 
between NOMAC/E2 and LNG/EE. For all adrenal 
and thyroid indices, changes from baseline to cycle 3 
were similar to changes from baseline to cycle 6.     
  Androgens, androgen precursors, and SHBG 
  For androgens and androgen precursors, a decrease 
from baseline to cycle 6 was observed, which was 
      Table 1   Summary of participants  ’   characteristics at screening    .
  NOMAC/E2 
      (n     60) 
  LNG/EE 
      (n      58) 
  Total 
    (  n      118) 
Age (years), mean (SD) 28.2 (8.2) 29.1 (7 .8) 28.7 (8.0)
Race,   n   (%)
Black 1 (1.7) 0 1 (0.8)
White 59 (98.3) 58 (100.0) 117 (99.2)
Weight (kg), mean (SD) 62.8 (9.7) 61.7 (9.0) 62.3 (9.3)
BMI (kg/m  2  ), mean (SD) 23.0 (2.9) 22.3 (2.5) 22.7 (2.7)
Parity,   n   (%)
Never pregnant 35 (58.3) 34 (58.6) 69 (58.5)
No pregnancy        28 weeks 4 (6.7) 3 (5.2) 7 (5.9)
1 7 (11.7) 6 (10.3) 13 (11.0)
      2 14 (23.3) 15 (25.9) 29 (24.6)
Last contraceptive method used within 
three months prior to screening  *  ,   n   (%)
None 1 (1.7) 4 (6.9) 5 (4.2)
Combined oral contraceptive 19 (31.7) 22 (37 .9) 41 (34.7)
Progestogen-only-pill 3 (5.0) 1 (1.7) 4 (3.4)
IUD (hormonal) 5 (8.3) 1 (1.7) 6 (5.1)
IUD (non-hormonal) 1 (1.7) 2 (3.4) 3 (2.5)
Vaginal ring or transdermal patch 5 (8.3) 7 (12.1) 12 (10.2)
Foam, condom, suppositories, diaphragm 26 (43.3) 21 (36.2) 47 (39.8)
Smoking status
Smokers,   n   (%) 14 (23.3) 7 (12.1) 21 (17 .8)
Non-smokers,   n   (%) 46 (76.7) 51 (87 .9) 97 (82.2)
  NOMAC/E2, nomegestrol acetate/17  β  -oestradiol; LNG/EE, levonorgestrel/ethinylestradiol; SD, standard deviation; 
BMI, body mass index; NA, not applicable; IUD, intrauterine device. 
        *  Most important contraceptive method.         Effect of NOMAC/E2 on endocrine function/androgens  Å  gren et al.
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well tolerated. The most frequently reported AEs 
(for NOMAC/E2 and LNG/EE, respectively) were 
upper respiratory tract infection (six and ﬁ  ve par-
ticipants), headache (three and seven participants), 
and acne (two and four participants). One serious 
adverse event (SAE), the worsening of a congenital 
mitral valve leak, was reported in the NOMAC/E2 
group. Immediately after clinical evaluation, the 
woman was withdrawn from the study. No serious 
AEs were reported in the LNG/EE group. Eight 
women (four women in each group) discontinued 
treatment during the study because of an AE. Rea-
sons for discontinuation due to an AE included 
depression, nausea, and a combination of tachycar-
dia, pain in the calf, and weakness in the limb 
(NOMAC/E2). In the LNG/EE group, AEs that led 
      Table 2   Effects of nomegestrol acetate/17  β  -oestradiol and levonorgestrel/ethinylestradiol on adrenal and thyroid 
indices.   
  Nomegestrol acetate/17  b  -oestradiol   Levonorgestrel/ethinylestradiol 
  Index   Assessment   Mean   SD   Median   IQR   Mean   SD   Median   IQR 
Total 
cortisol
    (nmol/l)
Baseline 482 129 469 166 502 153 524 166
Cycle 3 610 186 607 221 975 215 1021 248
Cycle 6 608 167 580 193 944 183 952 207
Change from baseline 
to cycle 6
123 195 111 166 432 172 441 193
% change from 
baseline to cycle 6
32.9 45.3 24.9 39.8 97 .4 65.2 82.2 52.8
CBG
    (nmol/l)
Baseline 910 201 867 232 932 163 917 213
Cycle 3 1182 367 1091 326 2086 430 2069 588
Cycle 6 1116 253 1053 253 1980 389 1929 536
Change from baseline 
to cycle 6
220 264 194 225 1047 402 967 523
% change from 
baseline to cycle 6
27 .4 29.2 21.9 28.9 117 .7 53.4 111.0 81.0
TSH
    (mU/l)
Baseline 2.69 1.28 2.38 1.61 2.20 1.08 1.92 1.12
Cycle 3 3.03 1.52 2.71 1.77 3.78 10.23 2.52 1.61
Cycle 6 2.96 2.05 2.56 1.70 2.75 3.36 2.19 0.96
Change from baseline 
to cycle 6
0.25 1.75      0.04 1.16 0.50 3.07 0.11 0.91
% change from 
baseline to cycle 6
13.3 63.6      2.2 50.6 22.8 78.5 6.9 49.7
Free T  4 
    (pmol/l)
Baseline 14.0 1.6 14.0 1.9 14.1 1.5 14.0 2.2
Cycle 3 15.5 1.9 15.2 3.0 15.7 2.1 15.8 2.9
Cycle 6 15.9 2.0 15.8 2.5 15.7 2.1 15.3 3.3
Change from baseline 
to cycle 6
1.8 1.8 1.7 2.7 1.4 1.7 1.3 2.1
% change from 
baseline to cycle 6
13.4 13.8 11.8 19.1 10.2 11.9 9.5 14.2
TBG
    (mg/l)
Baseline 20.3 2.9 20.1 4.1 20.3 3.3 20.1 4.4
Cycle 3 24.0 2.8 24.4 3.8 28.1 4.7 28.2 6.8
Cycle 6 24.2 3.6 24.0 3.6 28.4 5.3 27 .9 7 .4
Change from baseline 
to cycle 6
4.0 3.9 4.3 4.0 7 .9 3.8 7 .7 5.4
% change from 
baseline to cycle 6
21.6 20.6 21.0 23.2 39.0 19.5 38.1 30.2
      SD, standard deviation; IQR, interquartile range; CBG, corticosteroid-binding globulin; TSH, thyroid-stimulating hormone; 
T  4  , thyroxine; TBG, thyroxine-binding globulin.     Effect of NOMAC/E2 on endocrine function/androgens    Å  gren et al.
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surrogate markers that are indicative of adrenal and 
thyroid function, androgens, and androgen precursors. 
It appears that NOMAC/E2 has less inﬂ  uence than 
LNG/EE on these indices. 
  While both treatments caused CBG and total cor-
tisol levels to rise, increases were signiﬁ  cantly greater 
in women who received LNG/EE. Elevated CBG, 
which is commonly observed with COC use, is 
to discontinuation included decreased sexual desire, 
nausea, and headache.         
    D I S C U S S I O N   
  This randomised study compared the effects of 
NOMAC/E2 administered in a 24-day regimen with 
LNG/EE administered in a 21-day regimen on 
      Table 3   Effects of nomegestrol acetate/17  β  -oestradiol and levonorgestrel/ethinylestradiol on androgenic indices.   
  Nomegestrol acetate/17  b  -
oestradiol   Levonorgestrel/ethinylestradiol 
  Index   Assessment   Mean   SD   Median   IQR   Mean   SD   Median   IQR 
Total testosterone
    (nmol/l)
Baseline 1.68 0.75 1.58 1.13 1.90 0.94 1.82 0.97
Cycle 3 1.12 0.60 1.04 0.77 0.91 0.56 0.89 0.80
Cycle 6 1.23 0.86 1.04 0.77 0.91 0.58 0.80 0.71
Change from baseline 
to cycle 6
     0.47 0.83      0.46 0.79     1.02 0.72     0.88 0.81
% change from baseline 
to cycle 6
     25.2 38.1      31.1 42.8     53.8 25.4     60.2 29.2
Free testosterone
    (pmol/l)
Baseline 24.5 14.9 20.8 13.9 26.3 16.6 24.3 17 .3
Cycle 3 12.3 6.4 10.4 10.5 10.0 6.7 10.4 10.4
Cycle 6 12.8 8.8 10.4 7 .0 9.9 6.7 6.9 10.4
Change from baseline 
to cycle 6
     12.2 13.6      10.4 10.4     16.6 14.0     13.9 15.7
% change from baseline 
to cycle 6
     41.5 39.4      50.4 33.5     57 .8 29.4     66.5 25.0
DHEAS
    (  μ  mol/l)
Baseline 4.9 2.2 4.6 2.6 5.2 2.3 5.0 3.0
Cycle 3 4.5 2.0 4.3 2.7 4.3 2.1 4.0 2.7
Cycle 6 4.3 1.8 4.2 1.8 4.0 1.9 3.5 2.2
Change from baseline 
to cycle 6
     0.7 1.6      0.7 1.3     1.3 1.2     1.1 1.2
% change from baseline 
to cycle 6
     10.1 23.9      14.0 27 .9     22.9 18.0     24.8 15.9
Androstenedione
    (nmol/l)
Baseline 9.6 3.5 9.0 4.1 10.3 3.9 9.4 4.4
Cycle 3 7 .6 2.5 7 .5 2.8 6.5 2.7 6.3 3.3
Cycle 6 8.2 3.0 8.1 3.6 7 .0 3.4 6.3 4.5
Change from baseline 
to cycle 6
     1.7 3.0      1.4 3.6     3.6 3.2     4.0 3.7
% change from baseline 
to cycle 6
     13.2 30.2      15.5 37 .3     33.0 27 .3     36.4 33.3
DHT
    (nmol/l)
Baseline 0.59 0.21 0.55 0.23 0.62 0.26 0.52 0.34
Cycle 3 0.61 0.25 0.58 0.27 0.47 0.21 0.47 0.31
Cycle 6 0.53 0.28 0.48 0.38 0.36 0.19 0.33 0.26
Change from baseline 
to cycle 6
     0.08 0.30      0.14 0.41     0.28 0.26     0.28 0.34
% change from baseline 
to cycle 6
     7. 3 4 7. 7      22.6 71.8     38.1 37 .8     48.3 38.4
      SD, standard deviation; IQR, interquartile range; DHEAS, dehydroepiandrosterone sulphate; DHT, dihydrotestosterone.     Effect of NOMAC/E2 on endocrine function/androgens  Å  gren et al.
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related to an oestrogen-induced increase in the hepatic 
synthesis of serum proteins  13,20,21  . The effect of oestro-
gens on protein synthesis in the liver is not counter-
acted by progestogens  20  . Consequently, the signiﬁ  cantly 
lesser increase in CBG observed in women taking 
NOMAC/E2 is likely the result of the substitution of 
EE with E2. This is in line with the ﬁ  ndings of a 
previously performed study, which showed that the 
effect of 2 mg oestradiol valerate (which is equivalent 
to 1.52 mg E2  22  ) on CBG was considerably less than 
that of 10   μ  g EE  15  . The elevations in total cortisol are 
probably caused by an increased concentration of 
CBG, resulting in de—creased clearance and not by 
a direct effect on adrenal function. This was also con-
cluded in previous studies that assessed the effects of 
COC use on total cortisol  14,23,24  . 
  The increase in TBG as seen in the NOMAC/E2 
group and to a greater extent in the LNG/EE group 
      Table 4   Effects of nomegestrol acetate/17 β   -oestradiol and levonorgestrel/ethinylestradiol on SHBG.    
  Nomegestrol acetate/17  b  -oestradiol   Levonorgestrel/ethinylestradiol 
  Index   Assessment   Mean   SD   Median   IQR   Mean   SD   Median   IQR 
SHBG
    (nmol/l)
Baseline 73.5 34.3 65.5 33.6 77 .5 26.2 76.5 40.6
Cycle 3 101.4 37 .1 96.3 55.5 103.7 35.5 93.9 47 .6
Cycle 6 108.2 43.6 107 .9 57 .8 99.8 31.5 98.3 30.8
Change from baseline 
to cycle 6
35.3 41.4 33.8 52.0 20.7 30.4 15.3 42.6
% change from 
baseline to cycle 6
61.7 67 .0 44.1 78.8 36.4 53.3 22.4 64.1
      SD, standard deviation; IQR, interquartile range; SHBG, sex hormone-binding globulin.     
      Table 5   Differences between treatment groups (nomegestrol acetate/17  β  -oestradiol versus levonorgestrel/
ethinylestradiol) in median absolute changes from baseline to cycle 6 for adrenal, thyroid, and androgenic indices.   
  Index 
  Difference in change from baseline to cycle 6
    NOMAC/E2 vs. LNG/EE 
  Estimate (95% CI)  ∗     p-value  ∗    ∗   
  Adrenal and thyroid indices 
Total cortisol (nmol/l)        303  (    359;     248)      0.001
CBG (nmol/l)        811  (    945;     689)      0.001
TSH (mU/l)        0.10  (    0.46;  0.27) 0.57
Free T  4   (pmol/l) 0.45 (     0.30;  1.10) 0.18
TBG (mg/l)        3.60  (    5.20;     2.20)      0.001
  Androgens and androgen precursors 
Total testosterone (nmol/l) 0.49 (0.28; 0.69)        0.001
Free testosterone (pmol/l) 3.50 (0.00; 7 .00) 0.13
DHEAS (  μ  mol/l) 0.63 (0.16; 1.07) 0.013
Androstenedione (nmol/l) 1.96 (0.87; 3.24)        0.001
DHT (nmol/l) 0.20 (0.08; 0.31)        0.001
  Other Index 
SHBG (nmol/l) 15.6 (3.2, 28.8) 0.019
        ∗  Point estimates of the difference and two-sided 95% conﬁ  dence intervals (CIs) by the Hodges-Lehmann approach.     
    ∗    ∗  Differences between groups; Cochran-Mantel-Haenszel test adjusted for age class using standardised midranks, 
applied on changes from baseline.     
  NOMAC/E2, nomegestrol acetate/17  β  -oestradiol; LNG/EE, levonorgestrel/ethinylestradiol; CBG, corticosteroid-
binding globulin; TSH, thyroid-stimulating hormone; T  4  , thyroxine; TBG, thyroxine-binding globulin; DHEAS, 
dehydroepiandrosterone sulphate; DHT, dihydrotestosterone; SHBG, sex hormone-binding globulin.     Effect of NOMAC/E2 on endocrine function/androgens    Å  gren et al.
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and sexual function cannot be determined in a rela-
tively small trial like this. The signiﬁ   cance of these 
ﬁ  ndings can only be determined in large clinical stud-
ies with a sufﬁ  ciently long duration of treatment. 
  Since we observed an imbalance in smokers between 
the treatment groups (23.3% vs. 12.1% in the NOMAC/
E2 and LNG/EE groups, respectively), we investigated 
this factor in more detail. Although smoking was shown 
to have a signiﬁ  cant effect on total cortisol, androstene-
dione, DHT, and SHBG, with larger increases (or less 
pronounced decreases) in smokers in comparison to 
non-smokers (results not shown), analysis of variance 
methods based on ranks showed that all treatment 
effects adjusted for smoking were completely consistent 
with the results unadjusted for smoking. 
  In summary, this study demonstrated that the 
monophasic COC NOMAC/E2 has less inﬂ  uence 
on surrogate markers of adrenal and thyroid func-
tion, androgens, and androgen precursors than LNG/
EE. Large clinical or retrospective studies will be 
needed to determine whether these differences in 
surrogate endpoints have any clinical relevance. 
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is also considered to be caused by the oestrogenic 
component of COCs  15,25,26  . As for CBG, the EE-
induced, dose-dependent increase in TBG is gener-
ally not suppressed by progestogens, although a 
progestogen with androgenic activity may counter-
act this effect to some extent  15  . A rise in TBG results 
in the reduced clearance of tri-iodothyronine (T  3  ) 
and T  4  , thus increasing total T  3   and T  4  . COC use, 
however, appears to have little or no effect on 
  physiologically active, free fractions of thyroid 
hormones  14,24  –  26  . Also, no signiﬁ  cant changes in free 
T  4   or in TSH were observed in either group after 
six months of treatment, which is in agreement with 
results from other studies  14,24,25  . 
  Both NOMAC/E2 and LNG/EE induced a drop 
in the concentrations of all androgens and androgen 
precursors, with far more pronounced decreases 
occurring in women receiving LNG/EE. In general, 
COCs suppress both ovarian and adrenal androgen 
synthesis, resulting in decreased levels of the andro-
gen precursors androstenedione and DHEAS, as well 
as free and total testosterone  26  . The more   pronounced 
drop in free testosterone relative to total testosterone 
in women receiving NOMAC/E2 is likely the result 
of the increase in SHBG, which was greater for 
NOMAC/E2 than for LNG/EE. LNG, a progesto-
gen with residual androgenicity, counteracts the EE-
induced increase in SHBG, while NOMAC, a 
non-androgenic progestogen, does not have this 
effect. While the suppression of androgenic activity 
may be a useful treatment in women with hyperan-
drogenic symptoms like acne, it may potentially also 
adversely affect sexual function in women  27  –  29  . 
  The main limitation of this study is the use of sur-
rogate endpoints. While the surrogate markers assessed 
in this study are indicative of adrenal and thyroid func-
tion, they do not directly assess endocrine function. In 
addition, the relevance of the drops in androgens and 
androgenic precursors on clinical endpoints like acne 
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